02607 SH PHARMA
- 11.320
- +0.100+0.89%
SH PHARMA News
Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17
Southwest Securities released a research report on April 11 stating that it gave Shanghai Pharmaceutical (601607.SH) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) pharmaceutical bu
Shanghai Pharmaceutical (601607): 23 years of steady revenue growth, and the innovation pipeline has entered a harvest period
Research Report Nuggets丨Zheshang Securities: Shanghai Pharmaceuticals' 23-year profits are under pressure in the short term, optimistic about the 24-year inflection point
Shanghai Pharmaceutical (601607): Under short-term pressure, optimistic about the 24-year inflection point
Shanghai Pharmaceutical (2607.HK): Steady revenue growth in 2023; innovative drugs ushered in a harvest period
Shanghai Pharmaceutical (601607): Steady revenue growth in 2023; innovative drugs ushered in a harvest period
Shanghai Pharmaceutical (601607): Revenue in 2023 is in line with expectations, and the commercial sector maintains good growth
Changes in A-shares | Shanghai Pharmaceutical once fell by more than 1%, and Damo lowered profit estimates and H-share target prices
Bank Ratings｜Daimo: Lowering the target price of Shanghai Pharmaceuticals to HK$18 to maintain “increased holdings” rating
Research Report Nuggets: Southwest Securities: Shanghai Pharmaceutical Innovation Pipeline Enters Harvest Period, Maintains “Buy” Rating
Shanghai Pharmaceutical (601607): Third quarter results highlight resilience, innovation pipeline enters harvest period
Shanghai Pharmaceutical (601607): Main business maintained healthy growth in the 1-3 quarter, marketing and management expenses were optimized year over year
Shanghai Pharmaceutical (601607): The innovative drug and traditional Chinese medicine sectors have increased year-on-year, and the transformation is speeding up
Shanghai Pharmaceutical (601607): The commercial sector is growing steadily, and the overall fee control effect is remarkable
Shanghai Pharmaceutical (601607) 2023 Interim Report Review: Vaccine Impairment Affects Profit and Steady Business Growth
Shanghai Pharmaceutical (601607): Commercial revenue grew more than expected, profit fell short of expectations
Shanghai Pharmaceutical (601607): Main business revenue has maintained healthy growth, and the industrial sector is growing brilliantly
Shanghai Pharmaceutical (601607): Pharmaceutical industry leader entering the acceleration window
Shanghai Pharmaceutical (601607): Transitory impairment affects accelerated recovery of profits and operating income
Analysis
Price Target
No Data
